Bicara Therapeutics Inc. Common Stock
Price Action
Technical Summary
STAGE 2 UPTRENDBicara Therapeutics Inc. Common Stock is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 87), indicating clear outperformance against the broad market. Earnings contraction of 109% provides fundamental context to the price action. Investors should exercise caution due to high volatility (79% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $22.71 | +4.72% | ABOVE |
| 50 SMA | $20.52 | +15.91% | ABOVE |
| 100 SMA | $18.56 | +28.10% | ABOVE |
| 150 SMA | $18.02 | +31.97% | ABOVE |
| 200 SMA | $16.40 | +45.04% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BCAX in an uptrend right now?
BCAX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BCAX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BCAX overbought or oversold?
BCAX's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is BCAX outperforming the market?
BCAX has a Relative Strength (RS) Rating of 87 out of 99. Yes, BCAX is a market leader, outperforming 87% of all stocks over the past 12 months.
Where is BCAX in its 52-week range?
BCAX is trading at $23.78, which is 98% of its 52-week high ($24.25) and 97% above its 52-week low ($7.80).
How volatile is BCAX?
BCAX has a Beta of 1.79 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.